title: Malignant colonic neoplasia in cats: 46 cases (1990-1996).
abstract: OBJECTIVE
  To evaluate a group of cats with malignant colonic neoplasia and to identify factors related to survival time.
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  46 cats with malignant colonic neoplasia.
  
  
  METHODS
  Information on signalment, diagnostic findings, histopathologic diagnosis, surgical procedure performed, identification of nodal metastasis at surgery, type of chemotherapy administered, and survival time was obtained from the medical record of each cat. A diagnosis of malignant colonic neoplasia had been established by histologic examination of endoscopic biopsy specimens (3 cats), biopsy specimens obtained during laparotomy (38), or necropsy specimens (5).
  
  
  RESULTS
  Mean age of cats was 12.5 years (range, 6 to 18 years). Ultrasonography was useful 84% of the time in localizing the mass to the intestine. Three cats had endoscopic biopsy, 9 had incisional biopsy, 21 had mass resection, and 8 had subtotal colectomy performed. Histopathologic diagnoses included adenocarcinoma (21 cats), lymphoma (19), mast cell tumor (4), and neuroendocrine carcinoma (2).
  
  
  CONCLUSIONS
  Obtaining clean margins at surgery seems to increase survival time in cats with malignant colonic neoplasia. Metastasis at the time of surgery decreases survival time. Data from this study indicate that the survival time of certain cats with colonic lymphoma may not be affected by chemotherapy. Cats with an unidentified colonic mass should receive a subtotal colectomy to increase survival time. Cats with colonic adenocarcinoma should receive a subtotal colectomy with consideration of doxorubicin administration to increase survival time.
authors.affiliation: Department of Surgery, The Animal Medical Center, New York, NY 10021, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Slawienski
authors.forename: G E
authors.initials: GE
authors.lastname: Mauldin
authors.forename: G N
authors.initials: GN
authors.lastname: Mauldin
authors.forename: A K
authors.initials: AK
authors.lastname: Patnaik
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000662:veterinary*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001706:Biopsy / Q000379:methods / Q000662:veterinary; D002371:Cat Diseases / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D002415:Cats; D003082:Colectomy / Q000379:methods / Q000662:veterinary; D003110:Colonic Neoplasms / Q000401:mortality / Q000473:pathology / Q000662:veterinary*; D004317:Doxorubicin / Q000627:therapeutic use; D004724:Endoscopy / Q000379:methods / Q000662:veterinary; D005260:Female; D008223:Lymphoma / Q000401:mortality / Q000473:pathology / Q000662:veterinary*; D008297:Male; D012515:Mast-Cell Sarcoma / Q000401:mortality / Q000473:pathology / Q000662:veterinary*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013754:Tetracyclines; D014463:Ultrasonography / Q000379:methods / Q000662:veterinary
chemical_list: D000900:Anti-Bacterial Agents; D013754:Tetracyclines; D004317:Doxorubicin